Soybean peptide
Cosmetic ingredientPlant-derived cosmetic peptide
Also known as: Soybean peptide QRPR, orb2563674, TP2667
Early evidence, mostly unproven in humans
- Regulatory standing. Cosmetic ingredient, not regulated as a drug
- Limited human data. Some human data exists, not conclusive
- Registered human trials. 2 registered studies on ClinicalTrials.gov
- 1 cited source. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Soybean peptide refers to short protein fragments derived from soy, used mainly as an ingredient in cosmetic and skin care products. The listed database formula corresponds to a specific small peptide, though the name is also used broadly for mixtures of soy protein hydrolysates, so the exact composition can vary by product. Soy peptides are thought to act as skin conditioning agents and have been studied in the lab for antioxidant and moisture-related effects.
What the evidence shows
There are about 161 published papers and 2 registered human trials, with no clear advanced-phase clinical testing, so the human evidence for any specific effect remains limited and not conclusive. It is not FDA-approved for any medical use and is regulated as a cosmetic ingredient.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Chemopreventive property of a soybean peptide (lunasin) that binds to deacetylated histones and inhibits acetylation.
Temperature effect on the non-volatile compounds of Maillard reaction products derived from xylose-soybean peptide system: Further insights into thermal degradation and cross-linking
His-His-Leu, an angiotensin I converting enzyme inhibitory peptide derived from Korean soybean paste, exerts antihypertensive activity in vivo.
Effect of soybean peptides against hydrogen peroxide induced oxidative stress in HepG2 cells via Nrf2 signaling.
Sources
- PubChem compound record (CID 9872412)
- Registered trials on ClinicalTrials.gov
- Published papers on Europe PMC
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.